Comparison of antisense oligonucleotide drug delivery systems

被引:45
|
作者
Weyermann, J
Lochmann, D
Zimmer, A
机构
[1] Karl Franzens Univ Graz, Dept Pharmaceut Technol, Inst Pharmaceut Sci, A-8010 Graz, Austria
[2] Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany
关键词
antisense oligonucleotide; nanoparticles; liposomes; protamine; proticles; polyoma; VPI; drug delivery systems; NMDA receptor;
D O I
10.1016/j.jconrel.2004.08.027
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Antisense oligonucleotides (AS-ONs) are specific drugs to inhibit gene expression at the transcriptional level. They possess a poor bioavailability and can be degraded by nucleases very rapidly. Therefore, a strong need for the development of oligonucleotide drug delivery systems exists. In the present study, two commercially available liposomes (DOTAP, lipofectin), one artificial virus capsoid (polyoma VP1), two cationic acrylate nanoparticles and two protamine-based nanoparticle preparations (proticles) were compared. Physical parameters of all carrier systems including z-average size, size distribution and surface charge regarding were determined. Cellular uptake was measured by a microplate fluorescence quantification method and, in addition, was visualized in mouse fibroblasts by confocal laser scan microscopy (CLSM). A comparison of cytotoxicity of the different drug delivery systems was performed in vitro using a MTT assay. Mouse fibroblasts which were stable transfected with the cDNA of a N-methyl-D-aspartate (NMDA) receptor also served as functional antisense oligonucleotide test system based on excitotoxicity (cell death). In addition, the efficiency of our oligonucleotide delivery systems was compared on the level of protein expression by Western blotting. Concluding the results, an increased uptake of the ON was found (2-18-fold) for all delivery systems compared to the free ON. Protamine-based nanoparticles showed a very low cytotoxicity in contradiction to all other carrier systems. Lipofectin could be identified as the most potent delivery system in terms of antisense effect, followed by protamine nanoparticles and DOTAP. Sequence-specific antisense effects up to 80% were observed in the functional cell death assay. The highest reduction of NMDA expression was obtained from liposomal preparations with approximately 60% analyzed by Western blot. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:411 / 423
页数:13
相关论文
共 50 条
  • [1] Antisense oligonucleotide therapeutics: Drug delivery and targeting
    Rojanasakul, YY
    ADVANCED DRUG DELIVERY REVIEWS, 1996, 18 (02) : 115 - 131
  • [2] The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
    Gagliardi, Maria
    Ashizawa, Ana Tari
    BIOMEDICINES, 2021, 9 (04)
  • [3] Nonviral delivery systems for antisense oligonucleotide therapeutics
    Huang, Si
    Hao, Xin-Yan
    Li, Yong-Jiang
    Wu, Jun-Yong
    Xiang, Da-Xiong
    Luo, Shilin
    BIOMATERIALS RESEARCH, 2022, 26 (01)
  • [4] Nonviral delivery systems for antisense oligonucleotide therapeutics
    Si Huang
    Xin-Yan Hao
    Yong-Jiang Li
    Jun‑Yong Wu
    Da-Xiong Xiang
    Shilin Luo
    Biomaterials Research, 26
  • [5] Antisense oligonucleotide drug design
    Schiavone, N
    Donnini, M
    Nicolin, A
    Capaccioli, S
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (07) : 769 - 784
  • [6] Delivery of antisense oligonucleotide to the cornea by iontophoresis
    Berdugo, M
    Valamanesh, F
    Andrieu, C
    Klein, C
    Benezra, D
    Courtois, Y
    Behar-Cohen, F
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2003, 13 (02): : 107 - 114
  • [7] Efficiency of antisense oligonucleotide drug discovery
    Bennett, CF
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2002, 12 (03): : 215 - 224
  • [8] Antisense oligonucleotide technologies in drug discovery
    Aboul-Fadl, Tarek
    EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (04) : 285 - 288
  • [9] Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
    Petrilli, Raquel
    Eloy, Josimar O.
    Marchetti, Juliana M.
    Lopez, Renata F. V.
    Lee, Robert J.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2014, 15 (09) : 847 - 855
  • [10] Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers
    Zimmer, A
    METHODS-A COMPANION TO METHODS IN ENZYMOLOGY, 1999, 18 (03): : 286 - 295